Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA

Oct 15 2013

• By Sarah Karlin-Smith

Related Content

Panel Backs Pfizer’s Tofacitinib For RA, With Narrower Indication

May 10 2012

Pfizer’s Tofacitinib Clears FDA Without Limited Indication

Nov 06 2012

Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally

Jul 22 2013

Related Companies

Pfizer Inc.

Amgen, Inc.

Novartis AG

Additional Topics

Clinical Trials BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window